Bente Brokstad Herlofson

Bente Brokstad Herlofson

Auto-generated profile, based on publicly available information

Bente Brokstad Herlofson

Faculty of Dentistry, University of Oslo, Oslo, Norway

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2012 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
PWPetter Wilberg
Petter Wilberg
MHMarianne J. Hjermstad
Marianne J. Hjermstad
SOStig Ottesen
Stig Ottesen
BHBente B. Herlofson
Bente B. Herlofson

21 March 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
KTKatherine Taylor
Katherine Taylor
CACecilie D. Amdal
Cecilie D. Amdal
KBKristin Bjordal
Kristin Bjordal
GAGuro Lindviksmoen Astrup
Guro Lindviksmoen Astrup
BHBente B. Herlofson
Bente B. Herlofson
SSSusanne Singer
Susanne Singer
The long-term problems of head and neck cancer survivors (HNCS) are not well known. In a cross-sectional international study aimed at exploring the long-term quality of life in this population, 1114 HNCS were asked to state their two most serious long-term effects. A clinician recorded the responses during face-to-face appointments. A list of 15 example problems was provided, but a free text field was also available. A total of 1033 survivors responded to the question. The most frequent problems were ‘dry mouth’ (DM) (n = 476; 46%), ‘difficulty swallowing/eating’ (DSE) (n = 408; 40%), ‘hoarseness/difficulty speaking’ (HDS) (n = 169; 16%), and ‘pain in the head and neck’ (PHN) (n = 142; 14%). A total of 5% reported no problems. Logistic regression adjusted for age, gender, treatment, and tumor stage and site showed increased odds of reporting DM and DSE for chemo-radiotherapy (CRT) alone compared to surgery alone (odds ratio (OR): 4.7, 95% confidence interval (CI): 2.5–9.0; OR: 2.1, CI: 1.1–3.9), but decreased odds for HDS and PHN (OR: 0.3, CI: 0.1–0.6; OR: 0.2, CI: 0.1–0.5). Survivors with UICC stage IV at diagnosis compared to stage I had increased odds of reporting HDS (OR: 1.9, CI: 1.2–3.0). Laryngeal cancer survivors had reduced odds compared to oropharynx cancer survivors of reporting DM (OR: 0.4, CI: 0.3–0.6) but increased odds of HDS (OR: 7.2, CI: 4.3–12.3). This study provides evidence of the serious long-term problems among HNCS.

1 December 2014 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
PWPetter Wilberg
Petter Wilberg
MHMarianne J. Hjermstad
Marianne J. Hjermstad
SOStig Ottesen
Stig Ottesen
BHBente Brokstad Herlofson
Bente Brokstad Herlofson

10 January 2025 in Journal of Cranio-Maxillofacial Surgery
Verified
Journal Article
Open access
DSDavid Steybe
David Steybe
PPPhilipp Poxleitner
Philipp Poxleitner
SASuad Aljohani
Suad Aljohani
BHBente Brokstad Herlofson
Bente Brokstad Herlofson
ONOurania Nicolatou-Galitis
Ourania Nicolatou-Galitis
MRMaximilian Russe
Maximilian Russe
The potential of large language models (LLMs) in medical applications is significant, and Retrieval-augmented generation (RAG) can address the weaknesses of these models in terms of data transparency and scientific accuracy by incorporating current scientific knowledge into responses. In this study, RAG and GPT-4 by OpenAI were applied to develop GuideGPT, a context aware chatbot integrated with a knowledge database from 449 scientific publications designed to provide answers on the prevention, diagnosis, and treatment of medication-related osteonecrosis of the jaw (MRONJ). A comparison was made with a generic LLM ("PureGPT") across 30 MRONJ-related questions. Ten international experts in MRONJ evaluated the responses based on content, language, scientific explanation, and agreement using 5-point Likert scales. Statistical analysis using the Mann-Whitney U test showed significantly better ratings for GuideGPT than PureGPT regarding content (p = 0.006), scientific explanation (p = 0.032), and agreement (p = 0.008), though not for language (p = 0.407). Thus, this study demonstrates RAG to be a promising tool to improve response quality and reliability of LLMs by incorporating domain-specific knowledge. This approach addresses the limitations of generic chatbots and can provide traceable and up-to-date responses essential for clinical practice.

24 January 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
PSPreet Bano Singh
Preet Bano Singh
AYAlix Young
Alix Young
AHAmin Homayouni
Amin Homayouni
LHLene Hystad Hove
Lene Hystad Hove
BPBeáta Éva Petrovski
Beáta Éva Petrovski
JJJanicke Jensen
Janicke Jensen
Senses of smell and taste, saliva flow, and dental status are considered as important factors for the maintenance of a good nutritional status. Salivary secretory rates, chemosensory function, burning mouth sensation, halitosis and dental status were investigated in 58 patients with primary Sjögren’s syndrome (pSS), 22 non-Sjögren’s syndrome sicca (non-SS) patients, and 57 age-matched healthy controls. A significantly greater proportion of patients with pSS and non-SS had ageusia, dysgeusia, burning mouth sensation, and halitosis compared to controls. Patients with pSS had significantly lower olfactory and gustatory scores, and significantly higher caries experience compared to controls. Patients with pSS and non-SS patients had significantly lower unstimulated and stimulated whole saliva secretory rates compared to controls. The findings indicated that several different aspects of oral health were compromised in both, patients with pSS and non-SS, and this may affect their food intake and, hence, their nutritional status. Although non-SS patients do not fulfill Sjögren’s syndrome classification criteria, they have similar or, in some cases, even worse oral complaints than the patients with pSS. Further studies are needed to investigate food preferences, dietary intake, and nutritional status in these two patient groups in relation to their health condition.

26 July 2021 in Cancer
Verified
Journal Article
Open access
PDF file
VEVera Ehrenstein
Vera Ehrenstein
UHUffe Heide-Jørgensen
Uffe Heide-Jørgensen
MSMorten Schiødt
Morten Schiødt
OAOlof Akre
Olof Akre
BHBente Brokstad Herlofson
Bente Brokstad Herlofson
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
BACKGROUND: Osteonecrosis of the jaw (ONJ) is an adverse effect of antiresorptive treatment. This study estimated incidence proportions and incidence rates of ONJ in cancer patients with bone metastases from solid tumors treated for the prevention of skeletal‐related events in routine clinical practice.METHODS: This cohort study in Denmark, Norway, and Sweden in 2011‐2018 included 3 treatment cohorts: a denosumab inception cohort (DEIC), a zoledronic acid inception cohort (ZAIC), and a denosumab‐switch cohort (DESC). The authors estimated 1‐ to 5‐year incidence proportions and incidence rates of ONJ overall, by cancer site (breast, prostate, or other solid tumor), and by country. ONJ diagnoses were confirmed by adjudication.RESULTS: There were 1340 patients in the DEIC, 1352 in the ZAIC, and 408 in the DESC. The median ages of the 3 cohorts were 70, 69, and 70 years, respectively; the proportions of men were 72.6%, 53.8%, and 48.3%, respectively; and the median follow‐up was 19.8, 12.9, and 13.3 months, respectively. The 5‐year incidence proportions of ONJ were 5.7% (95% confidence interval [CI], 4.4%‐7.3%) in the DEIC, 1.4% (95% CI, 0.8%‐2.3%) in the ZAIC, and 6.6% (95% CI, 4.2%‐10.0%) in the DESC. The corresponding ONJ incidence rates per 100 person‐years were 3.0 (95% CI, 2.3‐3.7), 1.0 (95% CI, 0.6‐1.5), and 4.3 (95% CI, 2.8‐6.3). Incidence proportions and incidence rates were highest in patients with prostate cancer and in Denmark.CONCLUSIONS: This study provides estimates of the risk of medically confirmed ONJ among patients initiating denosumab or zoledronic acid in routine clinical practice in 3 Scandinavian countries. The results varied by cancer site and by country.LAY SUMMARY: Denosumab and zoledronic acid reduce the risk of bone fractures, pain, and surgery in patients with advanced cancers involving bone. Osteonecrosis of the jaw (ONJ)—death of a jawbone—is a known side effect of treatment with denosumab or zoledronic acid. The authors examined almost 2900 denosumab‐ or zoledronic acid–treated patients with cancer in Denmark, Norway, and Sweden. Over the course of 5 years, ONJ developed in 5.7% of the patients whose initial treatment was denosumab, in 1.4% of the patients whose initial treatment was zoledronic acid, and in 6.6% of the patients who switched from zoledronic acid to denosumab.